Trial Profile
Pharmacokinetics and Safety of Solid Oral Posaconazole (MK-5592, POS) in Chinese Subjects at High Risk for Invasive Fungal Infections
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Posaconazole (Primary)
- Indications Mycoses
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 22 Apr 2020 Results Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection, published in the Advances in Therapy
- 26 May 2016 Status changed from active, no longer recruiting to completed.
- 04 May 2016 Planned End Date changed from 1 Apr 2016 to 1 May 2016.